In a global landscape marked by geopolitical complexities including inflation, conflicts, energy price fluctuations, and financial strains, investment opportunities and innovation dynamics have been challenged. As the industry navigates through a changing landscape, this session will explore how these uncertainties are shaping early-stage investment trends and consequently, strategies to forge successful partnerships.
What are the main current issues and opportunities in terms of financing and partnering in the EU biotech ecosystem compared to the US? Has the availability of capital really been affected at the seed and series A stages? Are there any emerging trends or innovative approaches in early-stage collaborations that have emerged as a response? What are the impacts on the negotiation and terms of early-stage partnerships? How are biotech start-ups and pharma companies making the most of the current reality? What is the outlook for life sciences dealmaking in 2024?
Moderator: Gilles Toulemonde, CEO, Inpart 
